Color Atlas of Physiology 2003 thieme
.pdf
A. Bile components and hepatic |
B. Enterohepatic circulation of bile salts |
|
secretion of bile |
|
|
Cholesterol |
Primary |
|
bile salts |
|
|
|
Cholesterol |
|
|
|
|
|
Secondary |
Liver |
From |
|
|
bile salts |
Taurine |
|
enterohepatic |
|
Synthesis |
circulation |
|
Glycine |
|
|
|
|
|
Portal vein |
|
|
Bile salts |
Lecithin |
Conjugated |
|
|
|
||
|
bile salts |
|
|
|
||
|
|
|
|
|
|
|
|
|
Biliary canaliculi |
|
Bile salt pool (2–4g) |
|
|
|
|
|
circulates |
|
||
|
|
|
Inorganic |
|
||
|
|
|
6–10 times a day |
|
||
Sinusoid |
|
|
electrolytes |
|
Secondary- |
|
|
|
H2O |
Common |
Bile |
||
|
|
|
active |
|||
|
|
|
Alkaline |
bile duct |
Na+ |
|
|
|
|
phosphatase |
|
symport |
10.12 |
|
|
|
|
|
Small intestine |
|
|
|
|
|
(terminal ileum) |
||
|
|
|
|
|
|
|
Drugs |
Glutathione |
|
|
|
Plate |
|
|
|
|
|
|
||
|
|
Glucuronic |
|
|
|
|
Hormones |
|
Hepatocyte |
|
|
|
|
|
acid |
|
|
|
|
|
|
|
|
|
|
Excretion |
|
Bilirubin |
|
|
Conjugation |
|
(0.6g/day) |
|
|
|
|
|
|
||
C. Bile flow |
|
|
|
|
|
|
|
|
|
|
|
Bile salt- |
|
Bile flow |
|
|
|
|
dependent |
|
|
|
|
Hepatocytes |
Bile salt- |
|
|
|
0 |
|
|
Bile ducts |
independent |
|
|
|
|
|
|
||
|
Concentration of bile salts in plasma |
|
|
|||
|
|
|
|
|||
D. Gallbladder |
|
|
H2O Na+ |
Vagus nerve |
|
Cl– |
|
C bile |
|
B bile |
|
1 |
|
|
|
ACh |
Fats |
|
|
|
|
2 |
Fatty acids |
|
|
|
|
CCK |
|
E. Micelle-mediated “dissolution” |
|
|
||||||||||
of cholesterol in the bile |
|
|
|
|||||||||
|
|
|
|
|
|
100 |
Separation: |
|
|
|
||
|
|
|
|
|
|
cholesterol crystals |
|
|
||||
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
( |
|
|
|
|
|
|
|
|
mol) |
80 |
20 |
pho |
|
|
|
|
|
|
|
|
|
|
s |
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
(% |
|
|
|
L |
|
|
||
|
|
|
|
|
|
|
ph |
|
|
|
||
|
|
|
|
|
|
|
ec |
|
|
|||
|
|
|
|
|
|
40 |
a |
|
|
|
||
|
|
|
|
60 |
|
|
|
|
||||
|
|
|
|
|
(% |
|
|
|
||||
|
|
|
|
|
ithin |
|
|
|||||
|
|
e |
r |
ol |
|
|
|
|||||
|
|
|
|
|
|
mol) |
|
|
|
|||
Chole |
st |
|
|
|
|
|
|
tidylcholine |
|
|
||
|
|
40 |
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
60 |
|
|
|
||
|
|
|
|
|
|
|
Micelle- |
) |
|
|
||
|
|
|
|
|
|
|
|
al.) |
|
|||
20 |
|
|
|
|
|
|
|
|||||
|
|
|
|
|
mediated |
|
||||||
|
|
|
|
|
|
|
|
“dissolution” |
et |
|
||
|
|
|
|
|
|
|
|
Small |
|
|||
0 |
|
|
|
|
80 |
60 |
40 |
|
20 |
100 |
249 |
|
100 |
|
|
|
|
0 |
(After |
||||||
|
|
|
|
|
|
Bile salts (%mol) |
|
|
|
|
||
Despopoulos, Color Atlas of Physiology © 2003 Thieme
All rights reserved. Usage subject to terms and conditions of license.
Excretory Liver Function—Bilirubin
|
The liver detoxifies and excretes many mostly |
||
|
lipophilic substances, which are either |
||
|
generated during metabolism (e.g., bilirubin or |
||
|
steroid hormones) or come from the intestinal |
||
|
tract (e.g., the antibiotic chloramphenicol). |
||
|
However, this requires prior biotransforma- |
||
|
tion of the substances. In the first step of the |
||
|
process, reactive OH, NH2 or COOH groups are |
||
|
enzymatically added (e.g., by monooxy- |
||
Digestion |
genases) to the hydrophobic substances. In the |
||
second step, the substances are conjugated |
|||
|
|||
|
with glucuronic acid, acetate, glutathione, gly- |
||
|
cine, sulfates, etc. The conjugates are now |
||
and |
water-soluble and can be |
either further |
|
processed in the kidneys and excreted in the |
|||
|
|||
Nutrition10 |
urine, or secreted into bile by liver cells and ex- |
||
Carriers. The canalicular membrane of hepatocytes |
|||
|
creted in the feces. Glutathione conjugates, for |
||
|
example, are further processed in the kidney |
||
|
excreted as mercapturic acids in the urine. |
||
|
contains various carriers, most of which are directly |
||
|
fueled by ATP (see also p. 248). The principal carriers |
||
|
are: MDR1 (multidrug resistance protein 1) for rela- |
||
|
tively hydrophobic, mainly cationic metabolites, |
||
|
MDR3 for phosphatidylcholine |
(!p. 248), and |
|
|
cMOAT (canalicular multispecific organic anion |
||
|
transporter = multidrug resistance protein MRP2) for |
||
|
conjugates (formed with glutathione, glucuronic |
||
|
acid or sulfate) and many other organic anions. |
||
|
Bilirubin sources and conjugation. Ca. 85% of |
||
|
all bilirubin originates from the hemoglobin in |
||
|
erythrocytes; the rest is produced by other |
||
|
hemoproteins like cytochrome (!A and B). |
||
|
When degraded, the globulin and iron com- |
||
|
ponents (!p. 90) are cleaved from hemoglo- |
||
|
bin. Via intermediate steps, biliverdin and fi- |
||
|
nally bilirubin, the yellow bile pigment, are |
||
|
then formed from the porphyrin residue. Each |
||
|
gram of hemoglobin yields ca. 35 mg of biliru- |
||
|
bin. Free unconjugated bilirubin (“indirect” |
||
|
bilirubin) is poorly soluble in water, yet lipid- |
||
|
soluble and toxic. It is therefore complexed |
||
|
with albumin when present in the blood (2 mol |
||
|
bilirubin : 1 mol albumin), but not when ab- |
||
|
sorbed by hepatocytes (!A). Bilirubin is con- |
||
|
jugated (catalyzed by glucuronyltransferase) |
||
|
with 2 molecules of UDP-glucuronate (synthe- |
||
250 |
sized from glucose, ATP and UTP) in the liver |
||
cells yielding bilirubin diglucuronide (“direct” |
|||
bilirubin). It is a water-soluble substance secreted into the biliary canaliculi by primary active transport mechanisms (cMOAT, see above).
Bilirubin excretion. 200–250 mg of bilirubin is excreted in the bile each day. Ca. 90% of it is excreted in the feces. In the gut, bacteria break bilirubin down into the colorless compound, stercobilinogen (!B). It is partly oxidized into stercobilin, the brown compound that colors the stools. About 10% of all bilirubin diglucuronide is deconjugated by intestinal bacteria and returned to the liver in this lipophilic form (partly as stercobilinogen) via enterohepatic circulation. A small portion (ca. 1%) reaches the systemic circulation and is excreted by the kidneys as urobilinogen = stercobilinogen (see below) (!B). The renal excretion rate increases when the liver is damaged.
Jaundice. The plasma bilirubin concentration normally does not exceed 17 µmol/L (= 1 mg/dL). Concentrations higher than 30 µmol/L (1.8 mg/dL) lead to yellowish discoloration of the sclera and skin, resulting in jaundice (icterus). Types of jaundice:
1.Prehepatic jaundice. When excessive amounts of bilirubin are formed, for example, due to increased hemolysis, the liver can no longer cope with the higher load unless the plasma bilirubin concentration rises. Thus, unconjugated (indirect) bilirubin is mainly elevated in these patients.
2.Intrahepatic jaundice. The main causes are (a) liver cell damage due to toxins (Amanita) or infections (viral hepatitis) resulting in the impairment of bilirubin transport and conjugation; (b) deficiency or absence of the glucuronyltransferase system in the newborn (Crigler–Najjar syndrome); (c) inhibition of glucuronyltransferase, e.g., by steroids; (d) impaired secretion of bilirubin into the biliary canaliculi due to a congenital defect (Dubin–Johnson syndrome) or other reasons (e.g., drugs, steroid hormones).
3.Posthepatic jaundice: Impairment of the flow of bile occurs due to an obstruction (e.g., stone or tumor) in the bile ducts, usually accompanied by elevated serum concentrations of conjugated (direct) bilirubin and alkaline phosphatase—both of which are normal components of bile.
Types 2a, 2d and 3 jaundice are associated with increased urinary concentrations of conjugated bilirubin, leading to brownish discoloration of the urine. In type 3 jaundice, the stools are gray due to the lack of bilirubin in the intestine and the resulting absence of stercobilin formation.
Despopoulos, Color Atlas of Physiology © 2003 Thieme
All rights reserved. Usage subject to terms and conditions of license.
A. Conjugation and secretion of bilirubin in the liver
Albumin |
|
|
cMOAT |
|
|
|
Bilirubin- |
Function—Bilirubin |
|
|
Bilirubin |
Glucuronyl- |
||
|
digluc- |
|||
|
Bilirubin |
transferase |
||
|
uronide |
|||
|
|
|
||
|
|
|
ATP |
|
|
UDP- |
|
Biliary |
|
|
glucuronic |
|||
|
acid |
|
canaliculi |
|
Albumin |
UTP |
|
UDP |
|
|
|
|||
|
Glucose |
|
|
Liver |
|
|
|
|
|
|
Blood |
Hepatocyte |
|
Excretory |
B. Bilirubin metabolism and excretion |
|
|
||
|
|
|
|
|
|
Blood |
Bilirubin |
|
10.13 |
Hb |
230 |
|
||
|
|
|||
6.5 |
|
mg/day |
|
|
g/day |
|
|
|
Plate |
|
Macro- |
|
|
|
|
phages |
|
|
|
|
|
|
|
|
|
Conjugation |
|
|
|
|
(glucuronyltransferase) |
|
|
|
Other |
|
|
|
|
sources |
|
Bile |
1 5 % |
|
|
Liver |
|
enterohepatic |
|
|
Bilirubin |
circulation |
|
|
|
|
|
||
|
|
diglucuronide |
|
|
|
Large intestine |
|
|
|
|
|
Bilirubin |
Urobilinogen |
|
Greater |
|
|
|
|
circulation |
|
|
|
|
|
|
|
Sterco- |
|
|
Small intestine |
bilinogen |
|
|
|
|
|
||
|
|
|
Stercobilin |
|
|
Kidney |
|
Urobilin |
|
|
|
|
|
|
|
|
= Anaerobic |
|
|
|
|
bacteria |
|
|
|
1 % |
= O2 |
|
|
|
|
85 % |
251 |
|
|
in urine |
|
||
|
|
in feces |
||
|
(urobilin, etc.) |
|
|
|
|
|
|
|
|
Despopoulos, Color Atlas of Physiology © 2003 Thieme
All rights reserved. Usage subject to terms and conditions of license.
Lipid Digestion
|
The average intake of fats (butter, oil, mar- |
|
|
garine, milk, meat, sausages, eggs, nuts etc.) is |
|
|
roughly 60–100 g/day, but there is a wide |
|
|
range of individual variation (10–250 g/day). |
|
|
Most fats in the diet (90%) are neutral fats or |
|
|
triacylglycerols (triglycerides). The rest are |
|
|
phospholipids, cholesterol esters, and fat- |
|
|
soluble vitamins (vitamins A, D, E and K). Over |
|
|
95% of the lipids are normally absorbed in the |
|
Digestion |
small intestine. |
|
Lipid digestion (!A). Lipids are poorly |
||
|
||
|
soluble in water, so special mechanisms are re- |
|
|
quired for their digestion in the watery en- |
|
and |
vironment of the gastrointestinal tract and for |
|
their subsequent absorption and transport in |
||
Nutrition |
plasma (!p. 254). Although small quantities |
|
before they can be efficiently absorbed. Opti- |
||
|
of undegraded triacylglycerol can be absorbed, |
|
|
dietary fats must be hydrolyzed by enzymes |
|
10 |
mal enzymatic activity requires the prior me- |
|
chanical emulsification of fats (mainly in the |
||
|
||
|
distal stomach, !p. 240) because emulsified |
|
|
lipid droplets (1–2 µm; !B1) provide a much |
|
|
larger surface (relative to the mass of fat) for |
|
|
lipases. |
|
|
Lipases, the fat digesting enzymes, originate |
|
|
from the lingual glands, gastric fundus (chief |
|
|
and mucous neck cells) and pancreas (!A and |
|
|
p. 246). About 10–30% of dietary fat intake is |
|
|
hydrolyzed in the stomach, while the remain- |
|
|
ing 70–90% is broken down in the duodenum |
|
|
and upper jejunum. Lingual and gastric lipases |
|
|
have an acid pH optimum, whereas pancreatic |
|
|
lipase has a pH optimum of 7–8. Lipases be- |
|
|
come active at the fat/oil and water interface |
|
|
(!B). Pancreatic lipase (triacylglycerol hy- |
|
|
drolase) develops its lipolytic activity (max. |
|
|
140 g fat/min) in the presence of colipase and |
|
|
Ca2+. Pro-colipase in pancreatic juice yields |
|
|
colipase after being activated by trypsin. In |
|
|
most cases, the pancreatic lipases split triacyl- |
|
|
glycerol (TG) at the 1st and 3rd ester bond. This |
|
|
process requires the addition of water and |
|
|
yields free fatty acids (FFA) and 2-monoacyl- |
|
|
glycerol. |
A viscous-isotropic phase with aqueous and hydrophobic zones then forms around the enzyme (!B2).
252Ca2+ excesses or monoacylglycerol deficiencies result in the conversion of the fatty acids into calcium soaps,
which are later excreted.
Phospholipase A2 (from pro-phospholipase A2 in pancreatic juice—activated by trypsin) cleaves the 2nd ester bond of the phospholipids (mainly phosphatidylcholine = lecithin) contained in micelles. The presence of bile salts and Ca2+ is required for this reaction.
An unspecific carboxylesterase (= unspecific lipase = cholesterol ester hydrolase) in pancreatic secretions also acts on cholesterol esters on micelles as well as all three ester bonds of TG and esters of vitamins, A, D and E.
This lipase is also present in human breast milk (but not cow’s milk), so breast-fed infants receive the digestive enzyme required to break down milk fat along with the milk. Since the enzyme is heat-sensi- tive, pasteurization of human milk significantly reduces the infant’s ability to digest milk fat to a great extent.
2-Monoacylglycerols, long-chain free fatty acids and other lipids aggregate with bile salts (!p. 248) to spontaneously form micelles in the small intestine (!B3). (Since short-chain fatty acids are relatively polar, they can be absorbed directly and do not require bile salts or micelles). The micelles are only about 20–50 nm in diameter, and their surface-to- volume ratio is roughly 50 times larger than that of the lipid droplets in emulsions. They facilitate close contact between the products of fat digestion and the wall of the small intestine and are therefore essential for lipid absorption. The polar side of the substances involved (mainly conjugated bile salts, 2-mono- acylglycerol and phospholipids) faces the watery environment, and the non-polar side faces the interior of the micelle. Totally apolar lipids (e.g., cholesterol esters, fat-soluble vitamins and lipophilic poisons) are located inside the micelles. Thus, the apolar lipids remain in the lipophilic milieu (hydrocarbon continuum) during all these processes until they reach the lipophilic brush border membrane of the epithelium. They are then absorbed by the mucosa cells via dissolution in the membrane or by a passive transport mechanism (e.g., carriers in the case of free fatty acids). Although fat absorption is completed by the time the chyme reaches the end of the jejunum, the bile salts released from micelles are only absorbed in the terminal ileum and then recycled (enterohepatic circulation; !p. 249 B).
Despopoulos, Color Atlas of Physiology © 2003 Thieme
All rights reserved. Usage subject to terms and conditions of license.
A. Lipid digestion: overview
|
Dietary fats |
Stomach |
|
|
|
||
Mechanical emulsifi- |
Lipases from |
||
stomach and |
|||
cation by stomach |
|||
tongue |
|||
|
|
||
Degradation in |
Bile salts |
|
|
|
|
||
stomach (10–30%) |
|
Pancreatic lipase |
|
|
|
|
Pancreas |
|
|
|
Duodenum |
|
|
|
Digestion |
Degradation and micelle |
|
|
Excreted as |
||
formation in duodenum and |
|
|
calcium soaps |
||
|
jejunum (70–95%) |
Absorption in intestine |
(ca. 5%) |
Lipid |
|
|
|
|
|
|
|
B. Lipid digestion: degradation and micelle formation |
|
|
10.14 |
||
|
|
Emulsification |
|
Stomach |
|
|
|
|
Plate |
||
|
|
|
1–2 m |
|
|
|
|
|
|
|
|
|
|
1 Oil phase |
Emulsified |
|
|
|
|
|
|
|
|
|
TG |
|
triacylglycerols |
|
|
|
|
and other |
|
|
|
|
|
|
lipids |
|
|
|
|
|
Chyme |
|
|
|
Lipase |
|
|
|
|
MG+FFA |
H2O |
|
|
|
|
|
|
|
20–50nm |
|
|
|
BS |
|
|
|
|
2 Viscous–isotropic phase |
|
|
|
|
|
|
Triacylglycerol (TG) |
|
|
|
|
|
2-Monoacylglycerol (MG) |
|
Micelles |
|
|
|
|
|
|
|
|
|
Free fatty acids (FFA) |
|
Mucosal cell |
|
|
|
Apolar lipids |
|
|
|
|
|
|
|
|
253 |
|
|
Bile salts (BS) |
3 |
Micelle phase |
|
|
|
(After Patton) |
|
|||
|
|
|
|||
Despopoulos, Color Atlas of Physiology © 2003 Thieme
All rights reserved. Usage subject to terms and conditions of license.
10 Nutrition and Digestion
254
Lipid Distribution and Storage |
High-density lipoproteins (HDL) exchange |
|
certain apoproteins with chylomicrons and |
||
Lipids in the blood are transported in lipo- |
||
VLDL and absorb superfluous CHO from the |
||
proteins, LPs (!A), which are molecular |
extrahepatic cells and blood (!B). With their |
|
aggregates (microemulsions) with a core of |
ApoAI, they activate the plasma enzyme LCAT |
|
very hydrophobic lipids such as triacylglycerols |
(lecithin–cholesterol acyltransferase), which |
|
(TG) and cholesterol esters (CHO-esters) sur- |
is responsible for the partial esterification of |
|
rounded by a layer of amphipathic lipids |
CHO. HDL also deliver cholesterol and CHO- |
|
(phospholipids, cholesterol). LPs also contain |
esters to the liver and steroid hormone-pro- |
|
several types of proteins, called apolipo- |
ducing glands with HDL receptors (ovaries, |
|
proteins. LPs are differentiated according to |
testes, adrenal cortex). |
|
their size, density, lipid composition, site of |
|
|
synthesis, and their apolipoprotein content. |
Triacylglycerol (TG) |
|
Apolipoproteins (Apo) function as structural |
Dietary TGs are broken down into free fatty |
|
elements of LPs (e.g. ApoAII and ApoB48), lig- |
acids (FFA) and 2-monoacylglycerol (MG) in the |
|
ands (ApoB100, ApoE, etc.) for LP receptors on |
gastrointestinal tract (!C and p. 252). Since |
|
the membranes of LP target cells, and as |
short-chain FFAs are water-soluble, they can |
|
enzyme activators (e.g. ApoAI and ApoCII). |
be absorbed and transported to the liver via |
|
Chylomicrons transport lipids (mainly tri- |
the portal vein. Long-chain FFAs and 2-mono- |
|
acylglycerol, TG) from the gut to the periphery |
acylglycerols are not soluble in water. They are |
|
(via intestinal lymph and systemic circulation; |
re-synthesized to TG in the mucosa cells (!C). |
|
!D), where their ApoCII activates endothelial |
(The FFAs needed for TG synthesis are carried |
|
lipoprotein lipase (LPL), which cleaves FFA |
by FFA-binding proteins from the cell mem- |
|
from TG. The FFA are mainly absorbed by myo- |
brane to their site of synthesis, i.e., the smooth |
|
cytes and fat cells (!D). With the aid of ApoE, |
endoplasmic reticulum.) Since TGs are not |
|
the chylomicron remnants deliver the rest of |
soluble in water, they are subsequently loaded |
|
their TG, cholesterol and cholesterol ester load |
onto chylomicrons, which are exocytosed into |
|
to the hepatocytes by receptor-mediated en- |
the extracellular fluid, then passed on to the |
|
docytosis (!B, D). |
intestinal lymph (thereby by-passing the |
|
Cholesterol (CHO) and the TG imported |
liver), from which they finally reach the |
|
from the gut and newly synthesized in the liver |
greater circulation (!C, D). (Plasma becomes |
|
are exported inside VLDL (very low density |
cloudy for about 20–30 minutes after a fatty |
|
lipoproteins) from the liver to the periphery, |
meal due to its chylomicron content). The liver |
|
where they by means of their ApoCII also acti- |
also synthesizes TGs, thereby taking the re- |
|
vate LPL, resulting in the release of FFA (!D). |
quired FFAs from the plasma or synthesizing |
|
This results in the loss of ApoCII and exposure |
them from glucose. Hepatic TGs are loaded |
|
of ApoE. VLDL remnants or IDL (intermediate- |
onto VLDL (see above) and subsequently |
|
density lipoproteins) remain. Ca. 50% of the IDL |
secreted into the plasma (!D). Since the ex- |
|
returns to the liver (mainly bound by its ApoE |
port capacity of this mechanism is limited, an |
|
on LDL receptors; see below) and is re- |
excess of FFA or glucose (!D) can result in the |
|
processed and exported from the liver as VLDL |
accumulation of TGs in the liver (fatty liver). |
|
(!B). |
Free fatty acids (FFAs) are high-energy sub- |
|
The other 50% of the IDL is converted to LDL |
strates used for energy metabolism (!p. 228). |
|
(low density lipoprotein) after coming in con- |
Fatty acids circulating in the blood are mainly |
|
tact with hepatic lipase (resulting in loss of |
transported in the form of TG (in lipoproteins) |
|
ApoE and exposure of ApoB100). Two-thirds of |
whereas plasma FFA are complexed with al- |
|
the LDLs deliver their CHO and CHO-esters to |
bumin. Fatty acids are removed from TGs of |
|
the liver, the other third transfers its CHO to |
chylomicrons and VLDL by lipoprotein lipase |
|
extrahepatic tissue (!B). Binding of ApoB100 |
(LPL) localized on the luminal surface of the |
|
to LDL receptors is essential for both processes |
capillary endothelium of many organs (mainly |
|
(see below). |
in fat tissue and muscles) (!D). ApoCII on the |
|
|
! |
Despopoulos, Color Atlas of Physiology © 2003 Thieme
All rights reserved. Usage subject to terms and conditions of license.
A. Lipoproteins
Triacylglycerols |
Chylomicrons |
VLDL |
LDL |
|
HDL |
|
|||
|
|
|
|
0.08 |
|
|
|
||
|
Cholesterol |
|
|
|
|
|
|
|
|
|
|
|
|
0.12 |
|
|
|
|
|
|
esters |
0.86 g/g |
|
|
|
|
|
||
|
|
0.07 |
0.22 |
|
0.30 |
|
|||
|
Cholesterol |
|
|
0.55 |
|
I |
|||
|
|
|
0.18 |
0.42 |
|
0.47 |
Storage |
||
|
|
|
|
|
0.22 |
|
|||
|
Phospholipids |
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
0.03 |
|
|
|
|
0.04 |
||
|
|
|
|
|
0.06 |
|
|||
|
Proteins |
|
0.02 |
|
0.08 |
|
0.15 |
||
|
0.02 |
|
|
and |
|||||
|
|
0.07 |
|
|
|
|
0.04 |
||
|
Diameter |
80–500nm |
ca. 50nm |
ca. 20nm |
|
ca. 10nm |
|||
|
|
Distribution |
|||||||
Apolipoproteins |
AI, B48, CII+III, E |
B100, CII+III, E |
B100, CIII, E AI,III+IV, CIII, D |
||||||
B. Sources and fate of cholesterol |
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
Synthesis |
||
|
HDL |
Hepatocytes |
Endocytosis |
Lysosomal |
|
|
Lipid |
||
|
|
|
|
||||||
|
|
|
|
|
|
|
|
||
|
receptor |
|
|
LDL |
LDL |
lipases |
Cholesterin |
10.15 |
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
Extra- |
|
LDL |
|
|
|
|
Plate |
LDL |
HDL |
|
Receptor |
|
|
|
|||
hepatic cells |
|
CHO- |
|
|
|
|
|||
|
receptor |
|
|
|
|
|
|
|
|
|
LCAT |
|
|
|
esters |
ACAT |
|
|
|
|
|
|
|
(Store) |
|
|
|
||
|
|
|
|
|
|
|
|
||
contact |
|
|
|
|
|
|
Membranes, |
|
|
HDL |
|
|
|
|
steroid synthesis |
|
|||
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
Liver |
|
|
Synthesis |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liver |
|
|
|
IDL |
|
|
|
ca. 0.5g/day |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cholesterol |
|
|
Bile salts |
|
|
|
|
|
Chylom. |
|
|
|
|
|
|
|
|
|
residue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gut |
Enterohepaticcirculation: ca. 24g/day |
|
|
|
|
|
CHO-esters |
|
Diet: |
|
|
||
|
|
|
|
|
|
ca. 0.5g/day |
|
|
|
LPL |
|
|
|
|
|
Cholesterol |
|
|
|
|
|
|
|
|
CHO-esters |
|
|
||
|
|
|
|
Bile |
|
|
|||
|
LPL |
|
|
|
|
|
|||
|
|
|
|
|
Unspecific |
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
carboxyl |
|
|
|
|
|
|
|
Mucosa |
|
esterase |
|
|
|
|
|
|
|
|
|
|
|
|
|
VLDL |
|
|
|
|
|
Cell |
|
blood |
|
|
|
|
|
|
|
|
|
||
|
|
ca. 1g/day |
ACAT |
|
replacement |
|
|||
|
|
|
|
|
|
||||
Chylo- |
|
|
|
|
venous |
|
|||
|
|
|
|
|
|
|
|
||
microns |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Blood |
Intestinal |
Synthesis |
Stools: |
|
|
Portal |
255 |
|
|
lymph |
ca. 0.5g/day each |
|
||||||
Despopoulos, Color Atlas of Physiology © 2003 Thieme
All rights reserved. Usage subject to terms and conditions of license.
|
|
! |
|
|
surface of TGs and VLDL activates LPL. The in- |
|
|
sulin secreted after a meal induces LPL (!D), |
|
|
which promotes the rapid degradation of reab- |
|
|
sorbed dietary TGs. LPL is also activated by he- |
|
|
parin (from endothelial tissue, mast cells, etc.), |
|
|
which helps to eliminate the chylomicrons in |
|
|
cloudy plasma; it therefore is called a clearance |
|
|
factor. Albumin-complexed FFAs in plasma are |
|
|
mainly transported to the following target |
|
|
sites (!D): |
|
|
Cardiac muscle, skeletal muscle, kidneys and |
Digestion |
|
other organs, where they are oxidized to CO2 |
|
and H2O in the mitochondria (! oxidation) and |
|
|
|
used as a source of energy. |
|
|
Fat cells (!D), which either store the FFAs |
and |
|
or use them to synthesize TG. When energy re- |
|
quirements increase or intake decreases, the |
|
|
|
|
Nutrition |
|
FFAs are cleaved from triacylglycerol in the fat |
|
stimulated by epinephrine, glucagon and corti- |
|
|
|
cells (lipolysis) and transported to the area |
|
|
where they are needed (!D). Lipolysis is |
10 |
|
sol and inhibited by insulin (!p. 282ff.). |
|
The liver, where the FFAs are oxidized or |
|
|
|
|
|
|
used to synthesize TG. |
|
|
Cholesterol (CHO) |
|
|
|
|
|
Cholesterol esters (CHO-esters), like TGs, are |
|
|
apolar lipids. In the watery milieu of the body, |
|
|
they can only be transported when incor- |
|
|
porated in lipoproteins (or bound to proteins) |
|
|
and can be used for metabolism only after they |
|
|
have been converted to CHO, which is more |
|
|
polar (!B). CHO-esters serve as stores and in |
|
|
some cases the transported form of CHO. CHO- |
|
|
esters are present in all lipoproteins, but are |
|
|
most abundant (42%) in LDL (!A). |
|
|
Cholesterol is an important constituent of |
|
|
cell membranes (!p. 14). Moreover, it is a pre- |
|
|
cursor for bile salts (!B and p. 248), vitamin D |
|
|
(!p. 292), and steroid hormones (!p. 294ff.). |
|
|
Each day ca. 0.6 g of CHO is lost in the feces (re- |
|
|
duced to coprosterol) and sloughed off skin. |
|
|
The bile salt loss amounts to about 0.5 g/day. |
|
|
These losses (minus the dietary CHO intake) |
|
|
must be compensated for by continuous re- |
|
|
synthesis of CHO in the intestinal tract and |
|
|
liver (!B). CHO supplied by the diet is ab- |
|
|
sorbed in part as such and in part in esterified |
|
|
form (!B, lower right). Before it is reabsorbed, |
256 |
|
CHO-esters are split by unspecific pancreatic |
|
carboxylesterase to CHO, which is absorbed in |
|
|
|
the upper part of the small intestine (!B, bottom). Mucosal cells contain an enzyme that re-esterifies part of the absorbed CHO: ACAT (acyl-CoA-cholesterol acyltransferase) so that both cholesterol and CHO-esters can be integrated in chylomicrons (!A). CHO and CHOesters in the chylomicron remnants (see above) are transported to the liver, where lysosomal acid lipases again break the CHO-esters down into CHO. This CHO and that taken up from other sources (LDL, HDL) leave the liver (!B): 1. by excretion into the bile (!p. 248), 2. by conversion into bile salts which also enter the bile (!p. 249 B), and 3. by incorporation into VLDL, the hepatic lipoprotein for export of lipids to other tissues. Under the influence of LPL (see above), the VLDL yield IDL and later LDL (!B, left). The LDL transport CHO and CHO-esters to cells with LDL receptors (hepatic and extrahepatic cells; !B, top). The receptor density on the cell surface is adjusted according to the prevailing CHO requirement. Like hepatic cells (see above) extrahepatic cells take up the LDL by receptor-mediated endocytosis, and lysosomal acid lipases reduce CHOesters to CHO (!B, top right). The cells can then insert the CHO in their cell membranes or use it for steroid synthesis. A cholesterol excess leads to (a) inhibition of CHO synthesis in the cells (3-HMG-CoA-reductase) and (b) activation of ACAT, an enzyme that esterifies and stores CHO in the form of its ester (see above).
Hyperlipoproteinemia. An excess of lipids in the blood can be reflected by elevation of triacylglycerol levels and/or CHO levels (!200–220 mg/dL serum; affects about one in five adults in Western countries). In the most severe form, familial hypercholesterolemia, a genetic defect causes elevated plasma CHO concentrations from birth on, which can result in myocardial infarction in juvenile age. The disease is caused by genetic defects of the high-affinity LDL receptors. The serum CHO level rises since the cells take up smaller quantities of cholesterol-rich LDLs. Extrahepatic tissues synthesize larger quantities of CHO because 3-HMG-CoA-reductase fails to inhibit CHO synthesis due to the decreased absorption of LDLs. As a result, more LDLs bind to the low-affinity scavenger receptors that mediate the storage of CHO in macrophages, cutaneous tissues, and blood vessels. Hypercholesterolemia therefore increases the risk of arteriosclerosis and coronary disease.
Despopoulos, Color Atlas of Physiology © 2003 Thieme
All rights reserved. Usage subject to terms and conditions of license.
C. Fat absorption |
|
|
|
|
|
|
|
Fats |
Micelle |
|
|
|
Bile |
Liver |
|
|
Lipases |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Apolar lipids |
|
II |
|
|
Short-chain FFA |
|
|
|
Bile salts |
|
Storage |
|
|
|
|
|
|
||
Intestinal lumen |
|
|
|
|
|
Plate 10.16 Lipid Distribution and |
|
|
Glucose |
|
|
|
|
Enterohepatic circulation |
|
|
MG |
|
|
|
|||
|
TG |
|
|
|
|
||
|
TG |
|
|
|
|
||
|
synthesis |
Cholesterol |
|
|
Mucosal cell in Ileum |
||
|
|
|
|
||||
|
|
CHO-esters |
|
|
|||
|
|
Phospholipids |
|
||||
|
|
Fat-soluble vitamins |
|||||
Apolipoproteins |
|
|
Jejunum |
||||
|
|
Chylomicrons |
|
||||
Lymph |
|
To |
|
|
|
|
|
(Cf. legends for Plate 10.14B) |
systemic blood |
|
|
Portal venous blood |
|
|
|
|
|
|
|
|
|
||
D. Source and fate of triacylglycerols and free fatty acids |
|
|
|
||||
|
Intestine |
Free fatty acids (FFA) |
|
Intestinal lymph |
|||
|
Triacylglycerine (TG) |
|
|
||||
Diet |
|
|
and |
|
|
||
Glucose |
|
monoacylglycerol |
max. 15g/h |
||||
|
|
in micelles |
|||||
|
|
|
|||||
FFA |
Pancreatic |
|
|||||
Energy metabolism |
|
|
lipase |
|
|
|
|
Liver |
Pancreas |
|
in VLDL |
TG |
|
||
TG |
TG |
|
|
||||
|
|
|
|
|
|||
|
Storage |
|
|
|
4g/h |
In chylo- |
|
|
of excess fat |
|
|
|
microns |
||
|
Chylomicron |
Insulin |
|
|
max. |
|
|
|
residues and IDL |
|
|
|
|
|
|
|
|
|
|
LPL |
|
|
|
|
|
|
|
|
|
|
|
Blood |
|
FFA |
|
|
|
|
|
Release from |
|
|
|
|
|
|
|
stores 2–9g/h |
|
|
|
|
|
|
|
|
TG |
|
|
|
Energy metabolism |
|
|
|
|
|
|
|
|
||
Epinephrine |
|
Storage |
|
|
in muscle, heart, etc. |
|
|
|
|
|
|
|
257 |
||
Glucagon |
|
|
|
|
|
||
Cortisol |
|
in fat cells |
|
|
|
|
|
|
|
|
|
|
|
|
|
Despopoulos, Color Atlas of Physiology © 2003 Thieme
All rights reserved. Usage subject to terms and conditions of license.
Digestion and Absorption of
Carbohydrates and Protein
|
Carbohydrates provide half to two-thirds of |
|||||
|
the energy requirement (!p. 226). At least |
|||||
|
50% of dietary carbohydrates consist of starch |
|||||
|
(amylose and amylopectin), a polysaccharide; |
|||||
|
other important dietary carbohydrates are |
|||||
|
cane sugar (saccharose = sucrose) and milk |
|||||
|
sugar (lactose). Carbohydrate digestion starts |
|||||
|
in the mouth (!A1 and p. 236). Ptyalin, an α- |
|||||
Digestion |
amylase found in saliva, breaks starches down |
|||||
into oligosaccharides (maltose, maltotriose, α |
||||||
|
||||||
|
limit dextrins) in a neutral pH environment. |
|||||
|
This digestive process continues in the proxi- |
|||||
and |
mal stomach, but is interrupted in the distal |
|||||
stomach as the food is mixed with acidic gas- |
||||||
|
||||||
Nutrition |
tric juices. A pancreatic α-amylase, with a pH |
|||||
continue to the final |
oligosaccharide stage |
|||||
|
optimum of 8 is mixed into the chyme in the |
|||||
|
duodenum. Thus, polysaccharide digestion can |
|||||
10 |
mentioned above. The carbohydrates can be |
|||||
only absorbed in the form of monosaccharides. |
||||||
|
||||||
|
Thus, the enzymes maltase and isomaltase in- |
|||||
|
tegrated in the luminal brush border mem- |
|||||
|
brane of enterocytes break down maltose, mal- |
|||||
|
totriose and α limit dextrins into glucose as the |
|||||
|
final |
product. |
As in |
the renal |
tubules |
|
|
(!p. 158), glucose is first actively taken up by |
|||||
|
the Na+ symport carrier SGLT1 into mucosal |
|||||
|
cells (!A2, p. 29 B1) before passively diffusing |
|||||
|
into the portal circulation via GLUT2, the glu- |
|||||
|
cose |
uniport |
carrier |
(facilitated |
diffusion; |
|
!p. 22). The hydrolysis of saccharose, lactose, and trehalose is catalyzed by other brush border enzymes: lactase, saccharase (sucrase) and trehalase. In addition to glucose, these reactions release galactose (from lactose), which is absorbed by the same carriers as glucose, and fructose, which crosses the enterocytes by passive uniporters, GLUT5 in the luminal and GLUT2 in the basolateral membrane (!A2).
Lactase deficiency. Lactose cannot be broken down and absorbed unless sufficient lactase is available. Lactase deficiencies lead to diarrhea 1) because water is retained in the intestinal lumen due to osmotic mechanisms, and 2) because intestinal bacteria convert the lactose into toxic substances.
Protein digestion starts in the stomach (!B1). 258 HCl in the stomach denatures proteins and converts the three secreted pepsinogens into
about eight different pepsins. At a pH of 2–5, these endopeptidases split off proteins at sites where tyrosine or phenylalanine molecules are incorporated in the peptide chain. The pepsins become inactive in the small intestine (pH 7–8). Pancreatic juice also contains proenzymes of other peptidases that are activated in the duodenum (!p. 246). The endopeptidases trypsin, chymotrypsin and elastase hydrolyze the protein molecules into short-chain peptides. Carboxypeptidase A and B (from the pancreas) as well as dipeptidases and aminopeptidase (brush border enzymes) act on proteins at the end of the peptide chain, breaking them down into tripeptides, dipeptides, and (mostly) individual amino acids. These cleavage products are absorbed in the duodenum and jejunum.
Amino acids (AA) are transported by a number of specific carriers (!B2) similar to those found in the kidneys (!p. 158). Neutral (without net charge) and anionic (“acid”) L- amino acids are transported with Na+ symporters (secondary active transport; !p. 28) from the intestinal lumen into mucosal cells, from which they passively diffuse with carriers into the blood. Cationic (“basic”) L-amino acids such as L-arginine+, L-lysine+ and L-or- nithine+ are partly taken up into the enterocytes by Na+ independent mechanisms, as the membrane potential is a driving force for their uptake. Anionic amino acids like L-glutamate– and L-aspartate– which, for the most part, are broken down in the mucosal cells, also have their own (Na+ and K+ dependent) carrier systems. Neutral amino acids use several different transporters.
AA absorption disorders can be congenital and affect various amino acid groups. These disorders are often associated with defects of renal tubular reabsorption (renal aminoaciduria, e.g. cystinuria).
Dipeptides and tripeptides can be absorbed as intact molecules by a symport carrier (PepT1). The carrier is driven by an H+ gradient (!B2), which in turn is generated by H+ secretion (tertiary active H+-peptide symport, !p. 29 B5). Amino acids generally are much more rapidly absorbed as dipeptides and tripeptides than as free amino acids. Once they enter the cells, the peptides are hydrolyzed to free amino acids.
Despopoulos, Color Atlas of Physiology © 2003 Thieme
All rights reserved. Usage subject to terms and conditions of license.
